Drugs / MEDI0457
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial · 1 missed | ||||||
| Phase 1/2 | NCT03162224 | Jun 2017 → Mar 2021 | head and neck cancer, human papilloma virus infection | MedImmune LLC | Completed | Missed primary |
| Phase 22 trials | ||||||
| Phase 2 | NCT04001413 | Sep 2019 → Mar 2021 | human papillomavirus-related squamous cell carcinoma, oropharynx squamous cell carcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT03439085 | Nov 2018 → Sep 2022 | anal canal carcinoma, cervical carcinoma, metastatic malignant neoplasm, penile carcinoma +3 | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2019-04-08 | Inovio Pharmaceuticals | Inovio Achieves Third Cancer Indication Milestone for MEDI0457 Phase 2 Development inovio.com ↗ |
| 2018-01-08 | Inovio Pharmaceuticals | Inovio Receives Milestone Payment from MedImmune as MEDI0457 and Checkpoint Inhibitor Combination Trial in Head and Neck Squamous Cell Cancer Advances to Phase 2 inovio.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MEDI0457 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04001413 ↗ |
| Modality | Vaccine | “a HPV Deoxyribonucleic Acid (DNA) vaccine” NCT03162224 ↗ |
| Route | Intramuscular | “administered intramuscularly” NCT03162224 ↗ |